#ASCO21: AstraZeneca's PD-L1 Imfinzi tacks on 5-year survival data in NSCLC, which it's calling 'unprecedented'
Amid a sea of competitors in PD-(L)1, AstraZeneca has looked to outrun the big dogs in Merck and Bristol Myers Squibb with its Imfinzi. One …
Sign up to read this article for free.
Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.
